Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, Schaapveld M. Neppelenbroek SIM, et al. Among authors: te boome lcj. J Clin Oncol. 2024 Jun 1;42(16):1903-1913. doi: 10.1200/JCO.23.01386. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38359378
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM, Neppelenbroek SIM, Aleman BMP, Janus CPM, Krol ADG, van Spronsen DJ, Plattel WJ, Roesink JM, Verschueren KMS, Zijlstra JM, Koene HR, Nijziel MR, Schimmel EC, de Jongh E, Ong F, Te Boome LCJ, van Rijn RS, Böhmer LH, Ta BDP, Visser HPJ, Posthuma EFM, Bilgin YM, Muller K, van Kampen D, So-Osman C, Vermaat JSP, de Weijer RJ, Kersten MJ, van Leeuwen FE, Schaapveld M. Geurts YM, et al. Among authors: te boome lcj. ESMO Open. 2024 Feb;9(2):102248. doi: 10.1016/j.esmoop.2024.102248. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350338 Free PMC article.
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL, van Eijk R, Böhringer S, van Wezel T, Raghoo R, Ruano D, Jansen PM, Briaire-de Bruijn I, de Groot FA, Kleiverda K, Te Boome L, Terpstra V, Levenga H, Nicolae A, Posthuma EFM, Focke-Snieders I, Hardi L, den Hartog WCE, Bohmer LH, Hogendoorn PCW, van den Berg A, Diepstra A, Nijland M, Lugtenburg PJ, Kersten MJ, Pals ST, Veelken H, Bovée JVMG, Cleven AHG, Vermaat JSP. de Groen RAL, et al. Blood Adv. 2021 Oct 12;5(19):3760-3775. doi: 10.1182/bloodadvances.2021005215. Blood Adv. 2021. PMID: 34478526 Free PMC article.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Al-Sarayfi D, Meeuwes FO, Durmaz M, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PGNJ, Böhmer LH, van der Poel MWM, Te Boome L, van Meerten T, Chamuleau MED, Zijlstra JM, Brink M, Nijland M. Al-Sarayfi D, et al. Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4. Blood Cancer J. 2022. PMID: 36055987 Free PMC article. No abstract available.
Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ, Simmers TA, Alings AMW, Tieleman R, Klok FA, Huisman MV, Westerweel PE. van der Wall SJ, et al. Among authors: te boome lcj. Europace. 2019 Mar 1;21(3):414-420. doi: 10.1093/europace/euy220. Europace. 2019. PMID: 30339226
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib.
van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, van Dijk M, Raymakers R, Petersen E, de Witte M, de Jong N, Bellido M, Bär B, Meijer E, Kuball J. van der Wagen L, et al. Bone Marrow Transplant. 2018 Oct;53(10):1255-1262. doi: 10.1038/s41409-018-0158-9. Epub 2018 Mar 16. Bone Marrow Transplant. 2018. PMID: 29549292 Clinical Trial.
The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.
van Dorp S, Resemann H, te Boome L, Pietersma F, van Baarle D, Gmelig-Meyling F, de Weger R, Petersen E, Minnema M, Lokhorst H, Ebeling S, Beijn SJ, Knol EF, van Dijk M, Meijer E, Kuball J. van Dorp S, et al. Haematologica. 2011 Sep;96(9):1380-4. doi: 10.3324/haematol.2011.041814. Epub 2011 May 5. Haematologica. 2011. PMID: 21546493 Free PMC article. Clinical Trial.
19 results